• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Ultrahuman raises $17.5M Series B for wearable glucose monitoring tech

August 17, 2021 By Sean Whooley

Ultrahuman Cyborg
[Image from Ultrahuman]
Ultrahuman announced today that it raised $17.5 million in a Series B financing round for its wearable glucose tracking technology.

Bangalore, India-based Ultrahuman develops the Ultrahuman Cyborg, a continuous metabolism tracker designed to help people with diabetes track blood glucose in real-time and optimize their diet and exercise.

The platform goes beyond traditional markers like body mass index, weight and point-in-time blood tests, utilizing biomarkers to tell users how their body reacts to a certain type of food, how to fuel efficiently for exercise and how to eat for better sleep.

“Our mission is ‘to help people optimize their health by providing them access to deeply personalized insights and real-time nudges,'” the company wrote in a news release.

Ultrahuman said the funds raised in the Series B will give the company the ability to launch in new geographies, strengthen its teams and improve its life sciences research capabilities.

Alpha Wave Incubation (AWI), which is backed by DisruptAD and managed by Falcon Edge, Steadview Capital, Nexus Venture Partners, Blume Ventures and Utsav Somani’s iSeed fund all contributed to the financing. Additionally, angel investors, including Tiger Global’s Scott Schleifer, Sandeep Singhal, Kunal Shah, Sujeet Kumar, Deepinder Goyal, Gunjan Patidar, Gaurav Munjal, Revant Bhate, Mohit Gupta, Vikram Dhingra and Roman Saini also participated.

Filed Under: Business/Financial News, Diabetes, Featured, Funding Roundup, Patient Monitoring Tagged With: Ultrahuman

IN CASE YOU MISSED IT

  • Beta Bionics makes iLet available with Dexcom G7 15 Day CGM
  • Researchers say they can use imaging to measure blood glucose for people with diabetes
  • Dexcom launches program to enhance healthcare provider CGM knowledge
  • Insulet wins FDA clearance for Omnipod 5 algorithm enhancements
  • FDA accepts MannKind sNDA for autoinjector that treats edema

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS